Further data from two phase III TRuE-AD studies evaluating roxolitinib cream for atopic dermatitis meet quality of life endpoints

In TRuE-AD1 40.4% of patients treated with ruxolitinib 0.75% and 52.2% of patients treated with ruxolitinib 1.5% achieved reduction in itch v 15.4% on placebo (P<0.001 and P<0.0001 respectively). In TRuE-AD2, 42.7% and 50.7% respectively achieved this v 16.3% on placebo(P<0.0001)

SPS commentary:

The primary endpoint for the TRuE-AD1 and TRuE-AD2 studies was the proportion of patients achieving Investigator’s Global Assessment (IGA) Treatment Success (IGA-TS), defined as an IGA score of 0 (clear) or 1 (almost clear) with at least a two-point improvement from baseline, at Week 8. These have been reported previously.

Biospace Inc.

Resource links:

Other links